CAR-T cell therapy shows promise in treating autoimmune diseases

Clinical trials are showing promise for using CAR-T cell therapy to treat severe autoimmune diseases. In a study published in The New England Journal of Medicine, an innovative approach involving in vivo engineering of immune cells helped alleviate symptoms in 16 patients with multiple sclerosis and similar conditions.

This method uses a modified virus to deliver genetic instructions directly into the patient's body, instructing them to produce chimeric antigen receptor (CAR) T-cells. These cells are designed to identify and eliminate specific B-cells that produce harmful antibodies against the patient's own tissues.

In a separate study published in Nature Medicine, researchers at Charité – Universitätsmedizin Berlin reported that a CAR-T treatment, typically used for cancer, induced remission in patients with severe rheumatoid arthritis. The trial focused on patients with treatment-refractory cases, where the immune system's memory B-cells continue to drive inflammation despite standard therapies.